Sandalova, S., Dal, U. and Sandalov, A. (2026) “Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis”, International Journal of Medical Students. Available at: https://ijms.info/IJMS/article/view/4785 (Accessed: 30 August 2026).